SCD Care Partnerships Fulcrum's partnerships with MedicAlert Foundation and SCDAA to streamline ED access for people living with sickle cell disease demonstrate a proven model for care-plan distribution and rapid access in acute settings. Business development opportunities include partnering with major hospital ED networks and patient ID platforms to implement patient-specific care plans, integrate with EMR and ED workflows, and scale these programs through payer-backed access initiatives.

Rare Disease Collaboration The pociredir program for sickle cell disease and losmapimod exploration for facioscapulohumeral muscular dystrophy position Fulcrum as a developer of therapies for genetically defined rare diseases. This creates opportunities for out-licensing, co-development, or regional commercialization deals with pharma and biotech partners, along with targeted outreach to hematology, neuromuscular, and rare-disease clinics for trials and early access programs.

Market Visibility Active participation in high-profile conferences and investor events indicates strong market visibility and deal flow. Leverage JPMorgan, ASH, Goldman Sachs appearances to cultivate partnerships with health systems, payers, and CROs, while building pipeline-focused collaborations with academic centers and patient groups for trials, data sharing, and access programs.

Financial Flexibility A solid funding position provides strategic flexibility to pursue milestone-driven collaborations, upfront payments, and co-development arrangements. BD efforts can emphasize risk-sharing, aligned development timelines, and joint governance to accelerate therapy progression while maximizing potential returns for both Fulcrum and partners.

Digital Readiness Fulcrum's tech stack and digital footprint suggest readiness to collaborate on digital health solutions, data integration, and care-plan distribution. Opportunities exist to partner on EMR and hospital IT integrations, patient portals, and real-world evidence programs to support regulatory, payer, and patient access objectives.